Clinical trial
A Randomized Phase III Trial of the Duration of Anti-PD-1 Therapy in Metastatic Melanoma
NCT02821013 is registered in ClinicalTrials.gov with Canadian Cancer Trials Group as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized Phase III Trial of the Duration of Anti-PD-1 Therapy in Metastatic Melanoma
- Lead sponsor
- Canadian Cancer Trials Group
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- October 31, 2016
- Completion date
- December 31, 2029
- Enrollment
- 614 (estimated)
- Sites
- 30
Conditions
As the registry lists them; a condition with its own page is linked.
unresectable/metastatic melanoma